Why is Novartis driving R&D in global health?
Diseases such as malaria, dengue, leishmaniasis, Chagas and cryptosporidiosis hit some of the world's most vulnerable communities hardest, mostly in low- and middle-income countries. Yet these diseases have seen very little pharmaceutical innovation. Between 2005 and 2024, novel treatments for neglected tropical diseases and other global health conditions made up just 2% of approvals by the U.S. Food and Drug Administration. Staying the course in global health, our dedicated Novartis research teams aim to close this gap by discovering new medicines that help control and, ideally, eliminate these diseases.
"Some of these diseases have plagued humanity for thousands of years," says Thierry Diagana, Global Head Global Heath Research and California Sites Head. "Modern drug discovery gives us the chance to find new answers to these ancient problems. Our vision is to invent definitive therapeutics that change the practice of medicine for underserved populations."
How is Novartis addressing pressing global health issues through R&D?
Backed by more than USD 500 million in global health R&D investment since 2021, Novartis has built one of the largest pipelines in the sector for malaria and neglected tropical diseases. It includes around 10 new treatments, from early discovery to late-stage development. Among them are next-generation antimalarials to tackle rising drug resistance, a candidate for severe malaria and a potential first antiviral for dengue. The research teams work with philanthropies, academic institutions, governments and non-profit partners so that new medicines reach the people who need them.
"Every day, I work alongside scientists who are determined to solve long-neglected, urgent health challenges," says Diagana.